Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients

Sponsor
AbbVie
Study ID
NCT02333383
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — DRUG
    Adalimumab pre-filled syringe, administered by subcutaneous injection

Study Details

This was a prospective mono-country, multi-center study of the frequency of extra-axial manifestations (EAMs) in Ankylosing Spondylitis (AS) participants treated with adalimumab in routine clinical practice.

Key Dates

Start date
Dec 31, 2014
Status verified
Jul 2018
Primary completion
Aug 8, 2017
Completion
Aug 8, 2017

Study Design

Enrollment
201 participants (actual)

Arms

  • Arm: Participants with Ankylosing Spondylitis
    Adalimumab 40 mg every other week by subcutaneous (SC) injection for 52 weeks

Primary Outcome Measure

Frequency of Extra-Axial Manifestations (EAMs) of Interest [ Time Frame: Baseline ]

Related Studies